Santen SAS
Clinical Trials
26
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
Observational Survey Study on the Impact of Myopia and Its Complications on Quality of Life.
- Conditions
- Myopia
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Santen SAS
- Target Recruit Count
- 350
- Registration Number
- NCT06912802
LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.
- Conditions
- Acquired Blepharophimosis
- Interventions
- Other: Placebo (0% Oxymetazoline Hydrochloride) eye drops in single dose containers
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Santen SAS
- Target Recruit Count
- 234
- Registration Number
- NCT06514612
- Locations
- 🇨🇿
Oftex.s.r.o, oční klinika, Pardubice, Czechia
🇨🇿Fakultni nemocnice Plzeň, Oční oddělení, Plzen, Czechia
🇨🇿Fakultni Thomayerova nemocnice, Prague, Czechia
3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis
- Conditions
- Dry Eye Syndromes
- First Posted Date
- 2021-01-08
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Santen SAS
- Target Recruit Count
- 83
- Registration Number
- NCT04701086
- Locations
- 🇫🇷
CHRU Bretonneau, Tours, France
🇵🇱Gabinet Okulistyczny, Bielsko-Biala, Poland
🇵🇱Szpital SW. Rozy, Krakow, Poland
3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis
- Conditions
- Dry Eye Syndromes
- First Posted Date
- 2020-12-28
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Santen SAS
- Target Recruit Count
- 80
- Registration Number
- NCT04685109
- Locations
- 🇫🇷
Chru Brest Hopital Morvan, Brest, France
🇫🇷Cabinet Liberal, La Rochefoucauld, France
🇫🇷Hopital Edouard Herriot - Pavillon C, Lyon, France
3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)
- Conditions
- Dry Eye Disease With Severe Keratitis
- Interventions
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Santen SAS
- Target Recruit Count
- 350
- Registration Number
- NCT04144413
- Locations
- 🇨🇿
Fakultní Nemocnice Brno, Brno, Jihomoravský, Czechia
🇨🇿Fakultni Nemocnice Ostrava, Oční Klinika, Ostrava, Moravskoslezský, Czechia
🇨🇿University Hospital Hradec Kralove, Hradec Králové, Nový Hradec Králové, Czechia
- Prev
- 1
- 2
- 3
- Next